Press Releases

IGEM Therapeutics announces final close of £5 million Series A financing round

New investors Alsa Holdings and UCL Technology Fund join Epidarex Capital Proceeds will allow IGEM to continue development of IgE therapeutic antibody portfolio and...

Read more

IGEM Therapeutics awarded “Best Start-up Biotech Company” at the 2018 OBN Awards

London, 12 October 2018 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced...

Read more

IGEM Therapeutics shortlisted as a finalist in the “Best Start-up Biotech Company”

IGEM Therapeutics shortlisted as a finalist in the “Best Start-up Biotech Company” category of the 2018 OBN Awards  London, 22 August 2018– IGEM Therapeutics (IGEM)...

Read more

IGEM Therapeutics announces UK government funding to develop a novel IgE antibody targeting solid tumours

£1.45 million grant from Innovate UK Biomedical Catalyst Funds enable IGEM to progress second product candidate towards the clinic London, 9 May 2018 – IGEM...

Read more

IONTAS and IGEM Therapeutics collaborate to identify novel IgE antibodies for cancer targets

Cambridge, UK, 04 April 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced today that it will collaborate...

Read more

£2 million raised from Epidarex Capital

Raises £2 million from Epidarex Capital to progress pipeline of IgE antibody drug candidates to treat cancer

Read more